SCHEDULE: Vanguard Reports 5.13% Stake in Ultragenyx Pharma

Vanguard Capital Management has disclosed a beneficial ownership of 5.13% of Ultragenyx Pharmaceutical Inc.'s common stock as of June 30, 2026.

Summary

• Vanguard Capital Management, along with its affiliates and business divisions, now beneficially owns 5,058,419 shares of Ultragenyx Pharmaceutical Inc. common stock.
• This holding represents 5.13% of the total class of securities.
• The filing indicates Vanguard has sole dispositive power over these shares and sole voting power over 761,928 shares.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of influencing control of the issuer.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, indicating a substantial investment by a major player but without specific performance metrics or forward-looking statements from the company itself.

Positives

• Vanguard's significant stake suggests confidence in Ultragenyx Pharmaceutical's long-term prospects.
• The filing confirms that the shares are held in the ordinary course of business, implying a standard investment approach.

Risks

• Potential for Vanguard to adjust its holdings, which could impact share price due to its significant ownership percentage.

Future Outlook

The filing does not contain specific forward-looking statements or guidance from Vanguard regarding future ownership levels or strategy for Ultragenyx Pharmaceutical Inc.

Management Comments

• Vanguard Capital Management, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.
• No one other person's interest in the securities reported herein is more than 5%.

Industry Context

StockSavvy.ai notes that a significant institutional holding by a major asset manager like Vanguard in a biotechnology company like Ultragenyx Pharmaceutical often signals a positive view on the company's pipeline and market potential, especially in a sector driven by innovation and regulatory approvals.

Stakeholder Impact

• Shareholders may view Vanguard's significant stake as a positive endorsement, potentially increasing investor confidence.
• The market may interpret this as a sign of stability and institutional support for Ultragenyx Pharmaceutical Inc.

Next Steps

• Monitor future filings from Vanguard for any changes in beneficial ownership.
• Observe Ultragenyx Pharmaceutical Inc.'s performance and strategic updates for insights into the rationale behind Vanguard's investment.

Key Dates

Recommendation

The filing indicates a significant institutional holding by Vanguard, suggesting a level of confidence in Ultragenyx Pharmaceutical. However, as this is a Schedule 13G filing and not a company earnings report, it lacks specific operational or financial performance data from Ultragenyx itself. Therefore, a 'hold' recommendation is appropriate, pending further information on the company's performance and strategic direction.

Keywords

Ultragenyx Pharmaceutical, Vanguard Capital Management, Schedule 13G, Beneficial Ownership, Common Stock, Investment Management, Pharmaceuticals, Biotechnology